Genomics BioSci & Tech. Co.,Ltd.

TPEX:4195 Stock Report

Market Cap: NT$1.3b

Genomics BioSci & Tech.Ltd Past Earnings Performance

Past criteria checks 0/6

Genomics BioSci & Tech.Ltd's earnings have been declining at an average annual rate of -54.9%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been declining at an average rate of 1.4% per year.

Key information

-54.9%

Earnings growth rate

-51.6%

EPS growth rate

Biotechs Industry Growth12.2%
Revenue growth rate-1.4%
Return on equity-20.1%
Net Margin-38.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Is Genomics BioSci & Tech. Co.,Ltd.'s (GTSM:4195) 7.2% Dividend Worth Your Time?

Apr 27
Is Genomics BioSci & Tech. Co.,Ltd.'s (GTSM:4195) 7.2% Dividend Worth Your Time?

Key Things To Consider Before Buying Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) For Its Dividend

Jan 19
Key Things To Consider Before Buying Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) For Its Dividend

Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Nov 25
Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Revenue & Expenses Breakdown

How Genomics BioSci & Tech.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:4195 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24417-15814971
31 Mar 24407-16314764
31 Dec 23396-16814556
30 Sep 23401-12114750
30 Jun 23405-7514844
31 Mar 23412-214140
31 Dec 224197213436
30 Sep 224115812329
30 Jun 224024511123
31 Mar 223963211620
31 Dec 213901912117
30 Sep 214083112720
30 Jun 214264413322
31 Mar 214342213022
31 Dec 20443112623
30 Sep 20454712623
30 Jun 204651412724
31 Mar 204471612127
31 Dec 194281811630
30 Sep 19408-111733
30 Jun 19388-2011836
31 Mar 19382-2812141
31 Dec 18375-3612445
30 Sep 18397-3113150
30 Jun 18418-2713855
31 Mar 18429-3114050
31 Dec 17440-3614145
30 Sep 17401-4513738
30 Jun 17362-5513331
31 Mar 17369-5013130
31 Dec 16376-4413028
30 Sep 16397-3712425
30 Jun 16418-3011723
31 Mar 16409-3011121
31 Dec 15401-3010519
30 Sep 15379-3110318
30 Jun 15357-3210117
31 Mar 15337-3210023
31 Dec 14317-339929
30 Sep 14287-419734
30 Jun 14257-499639
31 Mar 14243-589332
31 Dec 13230-689126

Quality Earnings: 4195 is currently unprofitable.

Growing Profit Margin: 4195 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4195 is unprofitable, and losses have increased over the past 5 years at a rate of 54.9% per year.

Accelerating Growth: Unable to compare 4195's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4195 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).


Return on Equity

High ROE: 4195 has a negative Return on Equity (-20.14%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 09:15
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genomics BioSci & Tech. Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution